24/06/2025
BHRT in Practice Ep. 5 | Why Testosterone-Induced Erythrocytosis Isn’t Dangerous
There’s a common concern about testosterone therapy, that it increases the risk of blood clots by raising hemoglobin and hematocrit levels.
It’s important to understand the distinction:
🩸 Polycythemia vera is a blood disorder.
🧬 Testosterone-induced erythrocytosis is a known, manageable effect of therapy.
In this video, Dr Neal breaks down the evidence, clarifies common misunderstandings, and explores why testosterone isn’t necessarily the cardiovascular risk some assume, especially when managed appropriately.
✅ When monitored and prescribed responsibly, TRT doesn’t cause harmful blood thickening. Instead, it may help address underlying issues like metabolic syndrome, visceral fat, and insulin resistance, all key drivers of cardiovascular risk.
💡 The key?
Individualised care from providers experienced in hormone therapy, and coordination with specialists when needed.
Let’s move beyond myths and focus on the science.
If this resonates, like and share your thoughts below.
We’re here to make complex medicine clear, respectful, and real.